NO327465B1 - 2-oksasolaminer og deres anvendelse samt farmasoytisk sammensetning - Google Patents

2-oksasolaminer og deres anvendelse samt farmasoytisk sammensetning Download PDF

Info

Publication number
NO327465B1
NO327465B1 NO20043799A NO20043799A NO327465B1 NO 327465 B1 NO327465 B1 NO 327465B1 NO 20043799 A NO20043799 A NO 20043799A NO 20043799 A NO20043799 A NO 20043799A NO 327465 B1 NO327465 B1 NO 327465B1
Authority
NO
Norway
Prior art keywords
alkyl
optionally substituted
hydroxy
alkoxy
cycloalkyl
Prior art date
Application number
NO20043799A
Other languages
English (en)
Norwegian (no)
Other versions
NO20043799L (no
Inventor
Alexander William Oxford
Neil Victor Harris
Anthony Richard Borman
Lyle Kenneth Clark
Ann Janet Archer
George Hynd
Amanda Aley
Original Assignee
Pharmagene Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagene Lab Ltd filed Critical Pharmagene Lab Ltd
Publication of NO20043799L publication Critical patent/NO20043799L/no
Publication of NO327465B1 publication Critical patent/NO327465B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20043799A 2002-02-13 2004-09-10 2-oksasolaminer og deres anvendelse samt farmasoytisk sammensetning NO327465B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0203412.2A GB0203412D0 (en) 2002-02-13 2002-02-13 5-HT 2B receptor antagonists
PCT/GB2003/000552 WO2003068226A1 (fr) 2002-02-13 2003-02-11 2-oxazolamines et leur utilisation comme antagonistes du recepteur 5-ht2b

Publications (2)

Publication Number Publication Date
NO20043799L NO20043799L (no) 2004-09-10
NO327465B1 true NO327465B1 (no) 2009-07-06

Family

ID=9930999

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043799A NO327465B1 (no) 2002-02-13 2004-09-10 2-oksasolaminer og deres anvendelse samt farmasoytisk sammensetning

Country Status (17)

Country Link
US (1) US7429607B2 (fr)
EP (1) EP1474140B1 (fr)
JP (1) JP4439266B2 (fr)
KR (1) KR20040084905A (fr)
CN (1) CN1633291A (fr)
AU (1) AU2003207297B2 (fr)
CA (1) CA2472762A1 (fr)
DE (1) DE60317632T2 (fr)
EA (1) EA200401077A1 (fr)
GB (1) GB0203412D0 (fr)
IL (1) IL163110A (fr)
MX (1) MXPA04007738A (fr)
NO (1) NO327465B1 (fr)
NZ (1) NZ534539A (fr)
PL (1) PL370221A1 (fr)
WO (1) WO2003068226A1 (fr)
ZA (1) ZA200406010B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176791A1 (en) * 2002-02-13 2005-08-11 Oxford Alexander W. 5-HT2B receptor antagonists
CA2532505A1 (fr) * 2003-07-24 2005-02-10 Pharmagene Laboratories Limited Antagonistes du recepteur 5-ht<sb>2b</sb>
JPWO2005079845A1 (ja) 2004-02-20 2007-08-02 アステラス製薬株式会社 片頭痛予防薬
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
WO2005097113A2 (fr) * 2004-04-08 2005-10-20 Pharmagene Laboratories Limited Antagonistes du recepteur de la 5-ht2b
SG155996A1 (en) 2004-09-29 2009-10-29 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
WO2014085413A1 (fr) * 2012-11-28 2014-06-05 Temple University - Of The Commonwealth System Of Higher Education Oxazolidin-2-ones disubstituées, modulateurs de l'activité du récepteur 2b de 5-hydroxytryptamine
KR101592068B1 (ko) 2013-11-08 2016-02-05 순천향대학교 산학협력단 플라즈마 아포리포프로테인 h를 포함하는 아스피린 과민성 호흡계 질환 및 아스피린 내성 천식 구별 진단용 마커 및 구별 진단용 키트

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0658559A1 (fr) * 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Dérivés thiénothianine, procédé pour leur préparation et leur application comme inhibiteurs de 5-dipoxygenase et cyclooxygenase
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
CZ264996A3 (cs) 1994-03-11 1998-01-14 Eli Lilly And Company Použití sloučenin, které jsou aktivní na 5HT2B receptor
US6177452B1 (en) * 1996-04-03 2001-01-23 Takeda Chemical Industries, Ltd. Oxazole derivatives, their production and use
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
WO2000023444A1 (fr) * 1998-10-21 2000-04-27 Abbott Laboratories Composes de 4-aminopyrido[2,3-d]pyrimidine a disubstitution 5,7
CA2378710A1 (fr) 1999-07-30 2001-02-08 Pharmagene Laboratories Ltd. Utilisation de 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine pour le traitement des troubles gastro-intestinaux
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.

Also Published As

Publication number Publication date
EP1474140A1 (fr) 2004-11-10
EA200401077A1 (ru) 2005-06-30
JP2005528341A (ja) 2005-09-22
KR20040084905A (ko) 2004-10-06
AU2003207297A2 (en) 2003-09-04
GB0203412D0 (en) 2002-04-03
IL163110A (en) 2010-12-30
DE60317632T2 (de) 2008-10-30
PL370221A1 (en) 2005-05-16
DE60317632D1 (de) 2008-01-03
JP4439266B2 (ja) 2010-03-24
NO20043799L (no) 2004-09-10
US20040010022A1 (en) 2004-01-15
AU2003207297A1 (en) 2003-09-04
CA2472762A1 (fr) 2003-08-21
US7429607B2 (en) 2008-09-30
WO2003068226A1 (fr) 2003-08-21
ZA200406010B (en) 2005-06-08
NZ534539A (en) 2006-02-24
MXPA04007738A (es) 2004-10-15
AU2003207297B2 (en) 2008-11-06
CN1633291A (zh) 2005-06-29
EP1474140B1 (fr) 2007-11-21

Similar Documents

Publication Publication Date Title
AU2018214105B9 (en) Pyridone Amides as Modulators of Sodium Channels
JP6113789B2 (ja) 複素環化合物およびその用途
WO2020146682A1 (fr) Carboxamides utilisés en tant que modulateurs de canaux sodiques
AU728812B2 (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
AU2008341173B2 (en) Bis- (sulf onylamino) derivatives for use in therapy
AU2014290411A1 (en) Sulfonamides as modulators of sodium channels
WO2014120820A9 (fr) Amides comme modulateurs des canaux sodiques
JP2002513387A (ja) 選択的β▲下3▼アドレナリン作動性アゴニスト
JP2009538358A (ja) 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
NO332420B1 (no) EP4 reseptor antagonister, andvendelse derav og farmasoytisk sammensetning inneholdende en slik forbindelse
JP2008545686A (ja) 5ht6受容体を調節する新規な8−スルホニルアミノ−3アミノ置換クロマンまたはテトラヒドロナフタレン誘導体
JP2006528617A (ja) 5−ht2b受容体アンタゴニスト
US6011048A (en) Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
NO327465B1 (no) 2-oksasolaminer og deres anvendelse samt farmasoytisk sammensetning
CA3221960A1 (fr) Tetrahydrofuranes a substitution hydroxy et (halo)alkoxy utiles en tant que modulateurs de canaux sodiques
JPH10139780A (ja) 新規な複素環式アミノメチル化合物、これらの製造方法及びこれらを含む医薬組成物
BRPI0619282A2 (pt) sal de p-toluenossulfonato, sal, composição farmacêutica, método de modular ppar e uso de um sal
JP2005526720A (ja) 5−ht2b受容体アンタゴニスト
US7166624B2 (en) Peptide deformylase inhibitors
Oxford et al. 5–HT2B receptor antagonists
US20050176791A1 (en) 5-HT2B receptor antagonists
WO2005097113A2 (fr) Antagonistes du recepteur de la 5-ht2b
OA17449A (en) Pyridone amides as modulators of sodium channels.
MXPA00009950A (en) Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees